Literature DB >> 15455231

Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma.

Thomas Longerich1, Kai Breuhahn, Margarete Odenthal, Katharina Petmecky, Peter Schirmacher.   

Abstract

Transforming growth factor beta (TGFbeta) is a central mitoinhibitory factor for epithelial cells, and alterations of TGFbeta signalling have been demonstrated in many different human cancers. We have analysed human hepatocellular carcinomas (HCCs) for potential pro-tumourigenic alterations in regard to expression of Smad4 and mutations and expression changes of the pro-oncogenic transcriptional co-repressors Ski and SnoN, as well as mRNA levels of matrix metalloproteinase-2 (MMP2), which is transcriptionally regulated by TGFbeta. Smad4 mRNA was detected in all HCCs; while, using immunohistology, loss of Smad4 expression was found in 10% of HCCs. Neither mutations in the transformation-relevant sequences nor significant pro-tumourigenic expression changes of the Ski and SnoN genes were detected. In HCC cell lines, expression of both genes was regulated, potentially involving phosphorylation. Ski showed a distinct nuclear speckled pattern, indicating recruitment to active transcription complexes. MMP2 mRNA levels were increased in 19% of HCCs, whereas MMP2 mRNA was not detectable in HCC cell lines, suggesting that MMP2 was derived only from tumour stroma cells. Transcript levels of Smad4, Ski, SnoN and MMP2 correlated well. These data argue against a significant role of Ski and SnoN in human hepatocarcinogenesis and suggest that, in the majority of HCCs, the analysed factors are co-regulated by an upstream mechanism, potentially by TGFbeta itself.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455231     DOI: 10.1007/s00428-004-1118-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  37 in total

1.  Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease.

Authors:  A Maitra; K Molberg; J Albores-Saavedra; G Lindberg
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Proto-oncogene Sno expression, alternative isoforms and immediate early serum response.

Authors:  S Pearson-White; R Crittenden
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

3.  Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma.

Authors:  S Kawate; S Takenoshita; S Ohwada; A Mogi; T Fukusato; F Makita; H Kuwano; Y Morishita
Journal:  Int J Oncol       Date:  1999-01       Impact factor: 5.650

Review 4.  TGF-beta: a critical modulator of immune cell function.

Authors:  J J Letterio; A B Roberts
Journal:  Clin Immunol Immunopathol       Date:  1997-09

5.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 6.  TGF-beta and cancer.

Authors:  M Reiss
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

7.  Smad2 and Smad4 gene mutations in hepatocellular carcinoma.

Authors:  M C Yakicier; M B Irmak; A Romano; M Kew; M Ozturk
Journal:  Oncogene       Date:  1999-08-26       Impact factor: 9.867

8.  Loss of the SKI proto-oncogene in individuals affected with 1p36 deletion syndrome is predicted by strain-dependent defects in Ski-/- mice.

Authors:  Clemencia Colmenares; Heidi A Heilstedt; Lisa G Shaffer; Stuart Schwartz; Michael Berk; Jeffrey C Murray; Ed Stavnezer
Journal:  Nat Genet       Date:  2001-12-03       Impact factor: 38.330

Review 9.  The transforming growth factor-beta signaling pathway in tumorigenesis.

Authors:  R Wieser
Journal:  Curr Opin Oncol       Date:  2001-01       Impact factor: 3.645

10.  Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma.

Authors:  H Yamamoto; F Itoh; Y Adachi; H Sakamoto; M Adachi; Y Hinoda; K Imai
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

View more
  13 in total

1.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

2.  Impairment of transforming growth factor beta signaling in caveolin-1-deficient hepatocytes: role in liver regeneration.

Authors:  Rafael Mayoral; Ángela M Valverde; Cristina Llorente Izquierdo; Águeda González-Rodríguez; Lisardo Boscá; Paloma Martín-Sanz
Journal:  J Biol Chem       Date:  2009-12-05       Impact factor: 5.157

3.  Nesprin-1 impact on tumorigenic cell phenotypes.

Authors:  Ilknur Sur-Erdem; Muhammed Sajid Hussain; Maria Asif; Nareg Pınarbası; Ali Cenk Aksu; Angelika A Noegel
Journal:  Mol Biol Rep       Date:  2019-11-18       Impact factor: 2.316

4.  SKI knockdown inhibits human melanoma tumor growth in vivo.

Authors:  Dahu Chen; Qiushi Lin; Neil Box; Dennis Roop; Shunsuke Ishii; Koichi Matsuzaki; Tao Fan; Thomas J Hornyak; Jon A Reed; Ed Stavnezer; Nikolai A Timchenko; Estela E Medrano
Journal:  Pigment Cell Melanoma Res       Date:  2009-12       Impact factor: 4.693

5.  Liver stem cells and molecular signaling pathways in hepatocellular carcinoma.

Authors:  Krit Kitisin; Michael J Pishvaian; Lynt B Johnson; Lopa Mishra
Journal:  Gastrointest Cancer Res       Date:  2007

6.  Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.

Authors:  K Kitisin; N Ganesan; Y Tang; W Jogunoori; E A Volpe; S S Kim; V Katuri; B Kallakury; M Pishvaian; C Albanese; J Mendelson; M Zasloff; A Rashid; T Fishbein; S R T Evans; A Sidawy; E P Reddy; B Mishra; L B Johnson; K Shetty; L Mishra
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

Review 7.  Novel therapeutic strategies for targeting liver cancer stem cells.

Authors:  Naoki Oishi; Xin Wei Wang
Journal:  Int J Biol Sci       Date:  2011-04-26       Impact factor: 6.580

8.  Comparative analysis of TGF-β/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines.

Authors:  Johanna Dzieran; Jasmin Fabian; Teng Feng; Cédric Coulouarn; Iryna Ilkavets; Anastasia Kyselova; Kai Breuhahn; Steven Dooley; Nadja M Meindl-Beinker
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

9.  NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.

Authors:  Yuan Cao; Rahul Agarwal; Francesco Dituri; Luigi Lupo; Paolo Trerotoli; Serena Mancarella; Peter Winter; Gianluigi Giannelli
Journal:  Cell Death Dis       Date:  2017-02-23       Impact factor: 8.469

Review 10.  TGF-β - an excellent servant but a bad master.

Authors:  Lenka Kubiczkova; Lenka Sedlarikova; Roman Hajek; Sabina Sevcikova
Journal:  J Transl Med       Date:  2012-09-03       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.